FDA Approves Oral Formulation of Novo Nordisk’s Wegovy, Offering Daily Anti-Obesity Alternative

The US Food and Drug Administration (FDA) has granted approval to a novel oral formulation of Wegovy, a blockbuster anti-obesity medication developed by Novo Nordisk. The daily oral tablet, now available alongside the existing weekly injectable version, contains the same active ingredient, semaglutide, marking a significant advancement in the management of obesity through varied administration routes.

Key Details of the Oral Wegovy Approval

The oral formulation, designed for once-daily ingestion, is the result of intensified competition among pharmaceutical companies to develop oral GLP-1 agonists—a class of drugs that mimic naturally occurring hormones to reduce appetite and promote satiety. Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, noted: “This provides patients with obesity seeking weight loss the flexibility to choose between a weekly injection or a daily tablet.”

Clinical Efficacy and Adherence Considerations

Clinical trial data published in The New England Journal of Medicine demonstrated that participants receiving oral Wegovy achieved an average weight loss of 13.6% at 64 weeks, with nearly 30% of subjects losing ≥20% of their body weight. Notably, cardiovascular disease risk factors and physical activity levels improved comparably to the injectable Wegovy. However, investigators projected that optimal adherence to the daily regimen would yield an average weight loss of 16.6%, aligning with the injectable formulation’s efficacy.

Formulation Distinction from Rybelsus

Oral Wegovy differs from Novo Nordisk’s 2019-approved Rybelsus (14 mg), an oral semaglutide for type 2 diabetes. Unlike Rybelsus, the Wegovy pill is formulated at a higher dose (25 mg vs. 14 mg) to maximize weight-loss potential, as “higher doses are required to achieve full weight-loss efficacy for obesity,” Lange explained.

Safety and Side Effects

Common adverse effects of oral Wegovy—nausea and vomiting—are consistent with the injectable version, underscoring the formulation’s shared safety profile.

Pricing and Availability

Oral Wegovy will be launched in the US in early January with a starting dose of 1.5 mg, priced at $149 per month (with savings options). Novo Nordisk has initiated production at its US manufacturing facilities and expects sufficient supply to meet domestic demand.

Competitive Landscape

Eli Lilly, meanwhile, is advancing its daily GLP-1 oral candidate, orforglipron. Phase III trial results (August 2023) showed an average weight loss of 12.4% in obese individuals, slightly lower than injectable GLP-1 drugs (15–20% weight reduction). Unlike Wegovy, orforglipron has no food or water restrictions and is anticipated for FDA approval by year-end.

Industry Cost Projections

Pharmaceutical analyst Tim Blackstock of Citeline observed: “Oral and injectable GLP-1 formulations for diabetes exhibit similar costs, suggesting comparable pricing for obesity indications if efficacy remains aligned.”

Update (Monday, December 22, 7:25 pm ET): The article has been updated to include specific pricing and availability details for the oral Wegovy pill.

Source: FDA Approval Notice, Novo Nordisk, Eli Lilly, The New England Journal of Medicine (clinical trial data).